Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent

Proteasome is central to proteostasis network functionality and its over-activation represents a hallmark of advanced tumors; thus, its selective inhibition provides a strategy for the development of novel antitumor therapies. In support, proteasome inhibitors, e.g. Bortezomib or Carfilzomib have de...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Papanagnou, Eleni-Dimitra, Terpos, Evangelos, Kastritis, Efstathios, Papassideri, Issidora S., Tsitsilonis, Ourania E., Dimopoulos, Meletios A., Trougakos, Ioannis P.
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2018
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915155/
https://ncbi.nlm.nih.gov/pubmed/29707147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24882
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы